FDA Kicks Off BsUFA III Talks
Public Meeting Scheduled Ahead Of Reauthorization From 2023 Till 2027
The FDA has opened registration for a public meeting on reauthorizing the Biosimilar User Fee Act, for fiscal years 2023 through 2027.
The FDA has opened registration for a public meeting on reauthorizing the Biosimilar User Fee Act, for fiscal years 2023 through 2027.